Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.41 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.41 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.41 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
| ▸ | VEGFA | P15692 | 1/20 | 0.38 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.38 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20999795 | 1.00 | ALDH1A1 (0.49) | ALDH1A1L3MBTL1HTTS1PR1S1PR3 | |
| SCHEMBL6628592 | 0.94 | ALDH1A1 (0.44) | ALDH1A1L3MBTL1HTTS1PR1S1PR3 | |
| SCHEMBL4094412 | 0.84 | — | — | |
| SCHEMBL4080039 | 0.84 | — | — | |
| SCHEMBL3950159 | 0.84 | — | — | |
| SCHEMBL6636120 | 0.83 | S1PR1 (0.41) | ALDH1A1L3MBTL1HTTS1PR1S1PR3 | |
| SCHEMBL12064296 | 0.82 | ALDH1A1 (0.47) | ALDH1A1L3MBTL1HTTS1PR1S1PR3 | |
| SCHEMBL10181568 | 0.82 | ALDH1A1 (0.47) | ALDH1A1L3MBTL1HTTS1PR1S1PR3 | |
| SCHEMBL12064295 | 0.82 | ALDH1A1 (0.47) | ALDH1A1L3MBTL1HTTS1PR1S1PR3 | |
| SCHEMBL11647952 | 0.82 | S1PR1 (0.47) | ALDH1A1L3MBTL1HTTS1PR1S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260001838-A1 | NANOMATERIALS | GUIDE THERAPEUTICS LLC (US) | 2026-01-01 | — | — | US | disclosed |
| US-12435035-B2 | Nanomaterials | GUIDE THERAPEUTICS, LLC (US) | 2025-10-07 | — | — | US | disclosed |
| CN-119684140-A | Nanomaterial for the preparation of a nanoparticle | 盖德治疗有限责任公司 | 2025-03-25 | — | — | CN | disclosed |
| CN-115175894-B | Nanomaterial for the preparation of a nanoparticle | 盖德治疗有限责任公司 | 2024-09-06 | — | — | CN | disclosed |
| CN-115175894-A | Nano material | 盖德治疗有限责任公司 | 2022-10-11 | — | — | CN | disclosed |
| US-20210230112-A1 | NANOMATERIALS | GUIDE THERAPEUTICS, LLC | 2021-07-29 | — | — | US | disclosed |
| US-20210230112-A1 | NANOMATERIALS | GUIDE THERAPEUTICS, LLC | 2021-07-29 | — | — | US | disclosed |
| EP-0974602-B1 | Catalyst and process for hydrogenating olefinically unsaturated compound | JSR CORP (JP) | 2004-01-02 | — | — | EP | disclosed |
| US-6291596-B1 | CONTACTING OLEFINICALLY UNSATURATED COMPOUND WITH HYDROGEN IN THE PRESENCE OF A HYDROGENATION CATALYST COMPRISING TITANIUM OR ZIRCONIUM OR HAFNIUM COMPOUND IN AN INERT, ORGANIC SOLVENT | JSR CORPORATION (JP) | 2001-09-18 | — | — | US | disclosed |
| EP-0974602-A1 | Catalyst and process for hydrogenating olefinically unsaturated compound | JSR Corporation (JP) | 2000-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210230112-A1 | NANOMATERIALS | NPC1, NPC1L1, FABP1 | ALDH1A1 984/4885L3MBTL1 1211/4885HTT 2131/4885 |
| US-20260001838-A1 | NANOMATERIALS | SLC10A1, NPC1L1, FABP1 | ALDH1A1 619/4885L3MBTL1 523/4885HTT 1895/4885 |
| US-12435035-B2 | Nanomaterials | NPC1, NPC1L1, FABP1 | ALDH1A1 984/4885L3MBTL1 1211/4885HTT 2131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.